LIANY Stock - LianBio
Unlock GoAI Insights for LIANY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $-801,401 | $-1,327,000 | $-1,005,000 | $-526,000 | $-76,130 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-38,858,480 | $-99,543,000 | $-125,204,000 | $-195,570,000 | $-135,101,000 |
| Net Income | $2.48M | $311.14M | $-110,159,000 | $-196,561,000 | $-139,844,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $0.02 | $2.88 | $-1.02 | $-1.83 | $-1.33 |
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Visit WebsiteEarnings History & Surprises
LIANYEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2025 | Apr 25, 2025 | — | — | — | — |
Q1 2025 | Mar 28, 2025 | — | — | — | — |
Q4 2024 | Nov 18, 2024 | — | — | — | — |
Q3 2024 | Aug 9, 2024 | $-0.09 | — | — | — |
Q2 2024 | Apr 2, 2024 | $-0.19 | — | — | — |
Q1 2024 | Mar 25, 2024 | $-0.19 | $3.55 | +1968.4% | ✓ BEAT |
Q3 2023 | Sep 30, 2023 | $-0.33 | $-0.22 | +32.0% | ✓ BEAT |
Q2 2023 | Jun 30, 2023 | $-0.28 | $-0.20 | +30.0% | ✓ BEAT |
Q1 2023 | Mar 31, 2023 | $-0.27 | $-0.22 | +17.8% | ✓ BEAT |
Q4 2022 | Dec 31, 2022 | $-0.27 | $-0.17 | +38.1% | ✓ BEAT |
Q3 2022 | Sep 29, 2022 | $-0.39 | $-0.20 | +48.9% | ✓ BEAT |
Q2 2022 | Jun 29, 2022 | — | $-0.39 | — | — |
Q1 2022 | Mar 30, 2022 | $-0.28 | $-0.26 | +5.9% | ✓ BEAT |
Q4 2021 | Dec 30, 2021 | — | $-0.20 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.12 | — | — |
Q1 2021 | Mar 30, 2021 | — | $-3.00 | — | — |
Latest News
Frequently Asked Questions about LIANY
What is LIANY's current stock price?
What is the analyst price target for LIANY?
What sector is LianBio in?
What is LIANY's market cap?
Does LIANY pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to LIANY for comparison